Published 2009
| Version v1
Report
Open
Evaluation of the potential role of the new Cancer-Testis Antigen BORIS for the development of novel strategies of immunotherapy of cancer
- 1. Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome (Italy)
- 2. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (United States)
Description
BORIS/CTCFL (for brother of the regulator of imprinted sites), a paralogue of the transcription factor CTCF, is a recently described novel member of the cancer-testis (CT) antigen family (Loukinov D, et al. Proc Natl Acad Sci USA 2002;99:6806). BORIS expression appears to be restricted to testicular germ cells and to a vast majority of neoplastic cells including both cancer cell lines and primary tumors (Klenova EM, et al. Semin Cancer Biol 2002;12:399)
Files
40067961.pdf
Files
(134.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:67733b9d1f305a7bd92e74252d51b6a9
|
134.8 kB | Preview Download |
Additional details
Additional titles
- Original title (English)
- Programma di collaborazione ISS-NIH: relazioni conclusive dei progetti
Identifiers
- URL
- http://www.iss.it;
Publishing Information
- Imprint Title
- ISS-NIH Collaborative Programme: final report of the projects
- Imprint Pagination
- 467 p.
- Journal Page Range
- p. 245-247
- ISSN
- 1123-3117
- Report number
- ISTISAN--09-5
INIS
- Country of Publication
- Italy
- Country of Input or Organization
- Italy
- INIS RN
- 40067961
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANTIGENS; CARCINOGENESIS; IMMUNOTHERAPY; MEDICINE; NEOPLASMS; PEPTIDES; THERAPY
- Descriptors DEC
- DISEASES; MEDICINE; ORGANIC COMPOUNDS; PATHOGENESIS; PROTEINS; THERAPY
Optional Information
- Notes
- Imprint:Programma di collaborazione ISS-NIH: relazioni conclusive dei progetti